Join Growin Stock Community!

AlvotechALVO.US Overview

US StockHealthcare
(No presentation for ALVO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ALVO AI Insights

ALVO Overall Performance

ALVO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ALVO Recent Performance

-3.38%

Alvotech

0.05%

Avg of Sector

-0.31%

S&P500

ALVO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ALVO Key Information

ALVO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ALVO Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Price of ALVO

ALVO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ALVO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.22
PE Ratio (TTM)
17.35
Forward PE
-
PS Ratio (TTM)
2.17
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
55.59%
Net Margin
12.12%
Revenue Growth (YoY)
45.55%
Profit Growth (YoY)
37.08%
3-Year Revenue Growth
81.30%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.22
PE Ratio (TTM)
17.35
Forward PE
-
PS Ratio (TTM)
2.17
PB Ratio
-
Price-to-FCF
-
Gross Margin
55.59%
Net Margin
12.12%
Revenue Growth (YoY)
45.55%
Profit Growth (YoY)
37.08%
3-Year Revenue Growth
81.30%
3-Year Profit Growth
-%

  • When is ALVO's latest earnings report released?

    The most recent financial report for Alvotech (ALVO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ALVO's short-term business performance and financial health. For the latest updates on ALVO's earnings releases, visit this page regularly.

  • Where does ALVO fall in the P/E River chart?

    According to historical valuation range analysis, Alvotech (ALVO)'s current price-to-earnings (P/E) ratio is 23.05, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of ALVO?

    According to the latest financial report, Alvotech (ALVO) reported an Operating Profit of 1.31M with an Operating Margin of 1.15% this period, representing a decline of 89.68% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ALVO's revenue growth?

    In the latest financial report, Alvotech (ALVO) announced revenue of 113.86M, with a Year-Over-Year growth rate of 10.56%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ALVO have?

    As of the end of the reporting period, Alvotech (ALVO) had total debt of 1.28B, with a debt ratio of 0.91. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ALVO have?

    At the end of the period, Alvotech (ALVO) held Total Cash and Cash Equivalents of 42.85M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ALVO go with three margins increasing?

    In the latest report, Alvotech (ALVO) did not achieve the “three margins increasing” benchmark, with a gross margin of 69.3%%, operating margin of 1.15%%, and net margin of -4.6%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ALVO's profit trajectory and future growth potential.

  • Is ALVO's EPS continuing to grow?

    According to the past four quarterly reports, Alvotech (ALVO)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.03. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ALVO?

    Alvotech (ALVO)'s Free Cash Flow (FCF) for the period is -60.24M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 19.45% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.